Deal Details

Oculis Completes $40.3 Million Follow-On Offering

Healthcare

Oculis follow-on offering

Summary

Oculis Holding AG (“Oculis” or the “Company”) (NASDAQ: OCS), recently completed an underwritten public offering (the “Offering”) of ordinary shares for total gross proceeds of $40.3 million. Oculis intends to use the net proceeds from the Offering to advance its development programs in Diabetic Macular Edema and other ophthalmic indications, and for working capital and general corporate purposes.

The Offering consisted of 3,500,000 ordinary shares at a public offering price of $11.50 per share. In addition, Oculis has granted the underwriters a 30-day option to purchase up to an additional 525,000 ordinary shares.

Baird served as a co-manager on this offering.

About

Oculis is a global biopharmaceutical company purposefully driven to save sight and improve eye care. Oculis’ highly differentiated clinical-stage pipeline comprises multiple innovative product candidates in development for eye diseases of high unmet medical need. It includes OCS-01 eye drops, a topical candidate in Phase 3 development for diabetic macular edema (DME) and inflammation and pain following ocular surgery; OCS-02 eye drops, a topical biologic candidate in Phase 2b development for dry eye disease (DED) and uveitis; and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophthalmic disorders, such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The first in-patient, proof-of-concept trial with OCS-05 is currently ongoing in France. Oculis’ goal is to deliver life-changing eye treatments to patients worldwide. The Company is led by an experienced management team with a successful track record in the pharmaceutical industry, supported by leading international healthcare investors. Oculis Holding AG is headquartered in Zug, Switzerland and has operations in the United States, Europe and China.

Healthcare

Oculis follow-on offering